Stock Scorecard
Stock Summary for Kymera Therapeutics Inc (KYMR) - $46.44 as of 6/19/2025 7:51:31 PM EST
Total Score
6 out of 30
Safety Score
39 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KYMR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KYMR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KYMR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KYMR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KYMR (39 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for KYMR
Financial Details for KYMR
Company Overview |
|
|---|---|
| Ticker | KYMR |
| Company Name | Kymera Therapeutics Inc |
| Country | USA |
| Description | Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 46.44 |
| Price 4 Years Ago | 63.49 |
| Last Day Price Updated | 6/19/2025 7:51:31 PM EST |
| Last Day Volume | 517,555 |
| Average Daily Volume | 951,072 |
| 52-Week High | 53.27 |
| 52-Week Low | 19.45 |
| Last Price to 52 Week Low | 138.77% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 60.81 |
| Sector PE | 40.43 |
| 5-Year Average PE | -19.36 |
| Free Cash Flow Ratio | 33.65 |
| Industry Free Cash Flow Ratio | 19.08 |
| Sector Free Cash Flow Ratio | 31.51 |
| Current Ratio Most Recent Quarter | 8.49 |
| Total Cash Per Share | 1.38 |
| Book Value Per Share Most Recent Quarter | 12.07 |
| Price to Book Ratio | 3.84 |
| Industry Price to Book Ratio | 18.89 |
| Sector Price to Book Ratio | 30.07 |
| Price to Sales Ratio Twelve Trailing Months | 51.80 |
| Industry Price to Sales Ratio Twelve Trailing Months | 46.69 |
| Sector Price to Sales Ratio Twelve Trailing Months | 34.41 |
| Analyst Buy Ratings | 14 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 65,120,000 |
| Market Capitalization | 3,024,172,800 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -52.32% |
| Reported EPS 12 Trailing Months | -3.08 |
| Reported EPS Past Year | -0.82 |
| Reported EPS Prior Year | -2.91 |
| Net Income Twelve Trailing Months | -240,882,000 |
| Net Income Past Year | -223,858,000 |
| Net Income Prior Year | -146,962,000 |
| Quarterly Revenue Growth YOY | 114.80% |
| 5-Year Revenue Growth | 74.20% |
| Operating Margin Twelve Trailing Months | -336.80% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 89,966,000 |
| Total Cash Past Year | 120,256,000 |
| Total Cash Prior Year | 109,966,000 |
| Net Cash Position Most Recent Quarter | 89,966,000 |
| Net Cash Position Past Year | 120,256,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 835,619,000 |
| Total Stockholder Equity Prior Year | 394,971,000 |
| Total Stockholder Equity Most Recent Quarter | 786,233,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -240,341,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.69 |
| Free Cash Flow Past Year | -207,339,000 |
| Free Cash Flow Prior Year | -137,306,000 |
Options |
|
| Put/Call Ratio | 0.63 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 4.29 |
| MACD Signal | 4.06 |
| 20-Day Bollinger Lower Band | 19.95 |
| 20-Day Bollinger Middle Band | 33.65 |
| 20-Day Bollinger Upper Band | 47.35 |
| Beta | 2.07 |
| RSI | 65.77 |
| 50-Day SMA | 39.99 |
| 150-Day SMA | 32.09 |
| 200-Day SMA | 34.55 |
System |
|
| Modified | 6/19/2025 3:36:55 AM EST |